Skip to content

Effectiveness of the First French Psychoeducational Program on Unipolar Depression

Effectiveness of the First French Psychoeducational Program on Unipolar Depression: Study Protocol for a Randomized Controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02501226
Acronym
PURE
Enrollment
332
Registered
2015-07-17
Start date
2015-12-02
Completion date
2023-06-30
Last updated
2022-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Severity, Unipolar Depressed Outpatients, Without Psychotic Features

Keywords

Psychiatry, Depression, Psychoeducation, Randomized controlled trial, Treatment adherence, Remission

Brief summary

Background. Major Depressive Disorder (MDD) is highly prevalent and was associated with greater morbidity, mortality (including suicide), and healthcare costs. By 2030, MDD will become the leading cause of disability in high-income countries. Notably, among patients with a previous experience of a major depressive episode, it was indeed estimated that up to 85% of those patients will suffer from relapse. Two main factors were associated with a significantly higher risk of relapse: poor medication adherence and low self-efficacy in disease management. Interestingly, these issues could become the targets of psychoeducational programs for chronic diseases. Indeed psychoeducational program for depression are recommended in international guidelines, but have not yet been proposed in France. Methods/Design: The investigators propose to evaluate the first French psychoeducational program for depression named ENVIE in a multicenter randomized controlled trial. Its aim is to educate patients on the latest knowledge on depression and effective treatments through didactic and interactive sessions. Patients will experiment the latest innovating psychological skills (from acceptance and commitment therapy) to cope with depressive symptoms and maintain motivation in behavioral activation. In total, 332 unipolar non-chronic (\< 2 years) outpatients with moderate to severe depression, without psychotic features, will be randomly allocated to the add-on ENVIE program (N=166) or to a waiting list (N=166). The follow-up will last 15 months and include 5 assessment visits (enrollment, 3, 6, 9, 12, 15 months). Discussion. If the proposed trial shows the effectiveness of the intervention, but also an increased remission rate in depressed outpatients at 15-months post-inclusion, in addition to improved treatment adherence in patients, it will further promotes arguments in favor of a wide dissemination of psychoeducational programs for depression.

Detailed description

The investigators propose to study the rate of remission at 15-month follow-up and time to achieve remission of index episode in a multicentric randomized controlled trial using ENVIE program and treatment as usual versus treatment as usual only. The investigators will include depressed subjects suffering from non a first depressive episode as well as recurrent episode.The eligible patients will be randomized into two groups (computer-generated randomisation in a 1 :1 ratio, blocked in groups of 4, stratified on the number of episodes : 1 , 2 , 3 and more). Only outpatients consulting in the investigation centres will be recruited. Sociodemographic data, psychiatric diagnoses using Mini-International Neuropsychiatric Interview (M.I.N.I.) and Screening Interview for Axis II Disorder (SCID-II) for borderline personality disorder, pharmacological treatment will be also recorded. Patients will be assessed by clinicians blind to treatment allocation, at inclusion (before intervention) and at 3 months (end of the intervention), 6, 9 and 15 months after the inclusion.

Interventions

OTHERTreatment as usual

Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.

BEHAVIORALENVIE psychoeducational program

The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient. The sessions may be carried out remotely, by videoconference.

Sponsors

Centre Psychothérapique de Nancy
CollaboratorOTHER
Groupe Hospitalier de la Rochelle Ré Aunis
CollaboratorOTHER
Centre Hospitalier Universitaire de Besancon
CollaboratorOTHER
Centre Hospitalier Général de Béziers
CollaboratorUNKNOWN
University Hospital, Clermont-Ferrand
CollaboratorOTHER
Centre Hospitalier Universitaire de Nice
CollaboratorOTHER
Centre Hospitalier de l'Agglomération de Nevers
CollaboratorOTHER
Hôpitaux à Bron
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
CollaboratorOTHER
Centre Hospitalier Esquirol
CollaboratorOTHER
Centre Hospitalier Sainte-Marie, Nice
CollaboratorUNKNOWN
Centre Hospitalier Universitaire de Nīmes
CollaboratorOTHER
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* aged 18-65 years * with a main diagnosis of non-psychotic non-chronic (\<2 years) major depressive episode (DSM-IV criteria) of moderate to severe intensity (Montgomery Asberg Depression Scale score \> 24) * taking at least one antidepressant * able to speak, read and understand French * and able to give written informed consent

Exclusion criteria

* current psychotic features * duration of current depressive episode \>2 years * current organic mental disorder or mental retardation, or severe comorbid medical condition * lifetime history of schizophrenia, or schizoaffective or bipolar disorder, manic, hypomanic, or mixed episodes according to DSM-IV criteria * sensory or cognitive disabilities * having a relationship or being employed by the sponsor or investigator. * We will also exclude patients who are planning a long stay outside the region preventing compliance with the scheduled visits, and subjects participating in another trial.

Design outcomes

Primary

MeasureTime frameDescription
Rate of remission of index episode at 15-months without relapse during follow-up15 months after enrollmentThe primary endpoint will be the remission rate of the index episode at 15 months post-inclusion, defined by a Montgomery and Asberg Depression Rating Scale (MADRS) score ≤ 12 over an 8-week period, and without relapse during follow-up.

Secondary

MeasureTime frame
Evolution of MADRS and BDI scores during follow-up;At the enrollment, then at 3, 6, 9 and 15 months
Rate of response (decrease of MADRS score by 50%)At 15 months after enrollment
Rate of relapse (MADRS > 12 after remission of index episode)At 15 months after enrollment
Rate of hospitalisation during follow-up periodAt the enrollment, then at 3, 6, 9 and 15 months
Variation of global functioning using the Functioning Assessment Short TestBetween enrollment, and 9 and 15 months after enrollment
Variation of depressive intensity using Medication Adherence Rating Scale (MADRS)Between enrollment, and 3, 6, 9 and 15 months after enrollment
Variation of treatment adherence using MADRSBetween enrollment and 15 months after enrollment
Variation of benzodiazepines doses (data collection, no modification treatment according to the protocol)Between enrollment and 15 months after enrollment
Discontinuation rate of the antidepressant treatment .At 15 months after enrollment
Variation of depressive intensity using Beck Depression Inventory (BDI) scoresBetween enrollment, and 3, 6, 9 and 15 months after enrollment
Variation of quality of life using World Health Organization Quality Of Life measure-26Between enrollment, and 9 and 15 months after enrollment

Countries

France

Contacts

Primary ContactEmilie OLIE, MD, PhD
e-olie@chu-montpellier.fr00 33 4 67 33 82 89
Backup ContactDéborah DUCASS, MD
d-ducasse@chu-montpellier.fr00 33 4 67 33 82 89

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026